Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Biobran supplementation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer Stages I
1 trial -
Boost to the tumour bed
United Therapeutics Europe Ltd
Early Breast Cancer
1 trial -
Breast MRI interpretation
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Breztri Aerosphere
The First People's Hospital of Lianyungang
Lung Cancer, Nonsmall Cell
1 trial -
CT three-dimensional reconstruction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Cancer
1 trial -
Carbon Nanoparticle Suspension Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Carbon ion radiotherapy
Shanghai Proton and Heavy Ion Center
Pancreatic Cancer Non-resectable
1 trial -
Clostridium butyricum (live) Tablets(Meiya)
Rocket Pharmaceuticals B.V.
Rectal Cancer
1 trial -
Combination Product: Conventional third-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial -
Combination of chemotherapy and immunotherapy
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
Peking University Third Hospital
Prostate Cancer
1 trial -
Conventional second-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial -
Conventional third-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial -
Daphne Extract Capsules
The First People's Hospital of Lianyungang
Epithelial Ovarian Cancer
1 trial -
Dexmedetomidine
Shiyou Wei
Lung Cancer
1 trial -
Dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Dexmedetomidine-esketamine combination
The First People's Hospital of Lianyungang
Liver Cancer
1 trial -
Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Diclofenac
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Docetaxel
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Gefitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Gemcitabine
HALOZYME THERAPEUTICS, INC.
Pancreatic Cancer
1 trial -
Gemcitabine, cisplatin
The First People's Hospital of Lianyungang
Bladder Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources